Dietary Consumption of Edible Mushrooms for Disease Prevention: A Literature Overview †
Abstract
:1. Introduction
2. Methods
3. Results
4. Discussion
Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Wasser, S.P. The Importance of Culinary-Medicinal Mushrooms from Ancient Times to the Present. Int. J. Med. Mushrooms 2005, 7, 363–364. [Google Scholar] [CrossRef]
- Wang, X.-M.; Zhang, J.; Wu, L.-H.; Zhao, Y.-L.; Li, T.; Li, J.-Q.; Wang, Y.-Z.; Liu, H.-G. A Mini-Review of Chemical Composition and Nutritional Value of Edible Wild-Grown Mushroom from China. Food Chem. 2014, 151, 279–285. [Google Scholar] [CrossRef] [PubMed]
- You, S.W.; Hoskin, R.T.; Komarnytsky, S.; Moncada, M. Mushrooms as Functional and Nutritious Food Ingredients for Multiple Applications. ACS Food Sci. Technol. 2022, 2, 1184–1195. [Google Scholar] [CrossRef]
- Agrawal, D.C.; Dhanasekaran, M. (Eds.) Medicinal Mushrooms: Recent Progress in Research and Development, 1st ed.; Springer: Singapore, 2019; ISBN 9789811363818. [Google Scholar]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. Int. J. Surg. 2021, 88, 105906. [Google Scholar] [CrossRef]
- Ba, D.M.; Ssentongo, P.; Beelman, R.B.; Muscat, J.; Gao, X.; Richie, J.P. Higher Mushroom Consumption Is Associated with Lower Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies. Adv. Nutr. 2021, 12, 1691–1704. [Google Scholar] [CrossRef]
- Ba, D.M.; Gao, X.; Al-Shaar, L.; Muscat, J.; Chinchilli, V.M.; Ssentongo, P.; Zhang, X.; Liu, G.; Beelman, R.B.; Richie, J.P., Jr. Prospective Study of Dietary Mushroom Intake and Risk of Mortality: Results from Continuous National Health and Nutrition Examination Survey (NHANES) 2003–2014 and a Meta-Analysis. Nutr. J. 2021, 20, 80. [Google Scholar] [CrossRef]
- Dicks, L.; Ellinger, S. Effect of the Intake of Oyster Mushrooms on Cardiometabolic Parameters-A Systematic Review of Clinical Trials. Nutrients 2020, 12, 1134. [Google Scholar] [CrossRef]
- Krittanawong, C.; Isath, A.; Hahn, J.; Wang, Z.; Fogg, S.E.; Bandyopadhyay, D.; Jneid, H.; Virani, S.S.; Tang, W.H.W. Mushroom Consumption and Cardiovascular Health: A Systematic Review. Am. J. Med. 2021, 134, 637–642.e2. [Google Scholar] [CrossRef]
- Cardwell, G.; Bornman, J.F.; James, A.P.; Black, L.J. A Review of Mushrooms as a Potential Source of Dietary Vitamin D. Nutrients 2018, 10, 1498. [Google Scholar] [CrossRef]
- Mwangi, R.W.; Macharia, J.M.; Wagara, I.N.; Bence, R.L. The Antioxidant Potential of Different Edible and Medicinal Mushrooms. Biomed. Pharmacother. 2022, 147, 112621. [Google Scholar] [CrossRef]
- Sarikurkcu, C.; Tepe, B.; Yamac, M. Evaluation of the Antioxidant Activity of Four Edible Mushrooms from the Central Anatolia, Eskisehir—Turkey: Lactarius Deterrimus, Suillus Collitinus, Boletus Edulis, Xerocomus Chrysenteron. Bioresour. Technol. 2008, 99, 6651–6655. [Google Scholar] [CrossRef] [PubMed]
- Wang, X.; Lin, Z. Immunomodulating Effect of Ganoderma (Lingzhi) and Possible Mechanism. Adv. Exp. Med. Biol. 2019, 1182, 1–37. [Google Scholar] [CrossRef] [PubMed]
- Yuen, J.W.M.; Gohel, M.D.I. Anticancer Effects of Ganoderma Lucidum: A Review of Scientific Evidence. Nutr. Cancer 2005, 53, 11–17. [Google Scholar] [CrossRef]
- Antonelli, M.; Donelli, D.; Firenzuoli, F. Lentinan for Integrative Cancer Treatment: An Umbrella Review. Proceedings 2020, 83, 1. [Google Scholar] [CrossRef]
- Hsu, C.-H.; Liao, Y.-L.; Lin, S.-C.; Hwang, K.-C.; Chou, P. The Mushroom Agaricus Blazei Murill in Combination with Metformin and Gliclazide Improves Insulin Resistance in Type 2 Diabetes: A Randomized, Double-Blinded, and Placebo-Controlled Clinical Trial. J. Altern. Complement. Med. 2007, 13, 97–102. [Google Scholar] [CrossRef]
- Hashemi Yusefabad, H.; Hosseini, S.A.; Zakerkish, M.; Cheraghian, B.; Alipour, M. The Effects of Hot Air-Dried White Button Mushroom Powder on Glycemic Indices, Lipid Profile, Inflammatory Biomarkers and Total Antioxidant Capacity in Patients with Type-2 Diabetes Mellitus: A Randomized Controlled Trial. J. Res. Med. Sci. 2022, 27, 49. [Google Scholar] [CrossRef]
- Avinash, J.; Vinay, S.; Jha, K.; Das, D.; Goutham, B.S.; Kumar, G. The Unexplored Anticaries Potential of Shiitake Mushroom. Pharmacogn. Rev. 2016, 10, 100–104. [Google Scholar] [CrossRef]
- Fijałkowska, A.; Jędrejko, K.; Sułkowska-Ziaja, K.; Ziaja, M.; Kała, K.; Muszyńska, B. Edible Mushrooms as a Potential Component of Dietary Interventions for Major Depressive Disorder. Foods 2022, 11, 1489. [Google Scholar] [CrossRef]
- Zhao, H.; Zhang, Q.; Zhao, L.; Huang, X.; Wang, J.; Kang, X. Spore Powder of Ganoderma Lucidum Improves Cancer-Related Fatigue in Breast Cancer Patients Undergoing Endocrine Therapy: A Pilot Clinical Trial. Evid. Based. Complement. Alternat. Med. 2012, 2012, 809614. [Google Scholar] [CrossRef]
- Mori, K.; Inatomi, S.; Ouchi, K.; Azumi, Y.; Tuchida, T. Improving Effects of the Mushroom Yamabushitake (Hericium Erinaceus) on Mild Cognitive Impairment: A Double-Blind Placebo-Controlled Clinical Trial. Phytother. Res. 2009, 23, 367–372. [Google Scholar] [CrossRef]
- Morales, D.; Shetty, S.A.; López-Plaza, B.; Gómez-Candela, C.; Smidt, H.; Marín, F.R.; Soler-Rivas, C. Modulation of Human Intestinal Microbiota in a Clinical Trial by Consumption of a β-D-Glucan-Enriched Extract Obtained from Lentinula Edodes. Eur. J. Nutr. 2021, 60, 3249–3265. [Google Scholar] [CrossRef] [PubMed]
- Murphy, E.A.; Davis, J.M.; Carmichael, M.D. Immune Modulating Effects of β-Glucan. Curr. Opin. Clin. Nutr. Metab. Care 2010, 13, 656–661. [Google Scholar] [CrossRef] [PubMed]
- Lo, H.-C.; Wasser, S.P. Medicinal Mushrooms for Glycemic Control in Diabetes Mellitus: History, Current Status, Future Perspectives, and Unsolved Problems (review). Int. J. Med. Mushrooms 2011, 13, 401–426. [Google Scholar] [CrossRef] [PubMed]
- Kała, K.; Kryczyk-Poprawa, A.; Rzewińska, A.; Muszyńska, B. Fruiting Bodies of Selected Edible Mushrooms as a Potential Source of Lovastatin. Eur. Food Res. Technol. 2020, 246, 713–722. [Google Scholar] [CrossRef]
- O’Neil, C.E.; Nicklas, T.A.; Fulgoni, V.L. Mushroom Intake Is Associated with Better Nutrient Intake and Diet Quality: 2001–2010 National Health and Nutrition Examination Survey. J. Nutr. Food Sci. 2013, 3, 1000229. [Google Scholar]
- Johansson, L.; Tuomainen, P.; Anttila, H.; Rita, H.; Virkki, L. Effect of Processing on the Extractability of Oat β-Glucan. Food Chem. 2007, 105, 1439–1445. [Google Scholar] [CrossRef]
- Nieminen, P.; Mustonen, A.-M. Toxic Potential of Traditionally Consumed Mushroom Species-A Controversial Continuum with Many Unanswered Questions. Toxins 2020, 12, 639. [Google Scholar] [CrossRef]
- Thakur, M.P. Advances in Mushroom Production: Key to Food, Nutritional and Employment Security: A Review. Indian Phytopathol. 2020, 73, 377–395. [Google Scholar] [CrossRef]
- Kalač, P. A Review of Edible Mushroom Radioactivity. Food Chem. 2001, 75, 29–35. [Google Scholar] [CrossRef]
Population | Intervention | Comparison | Follow-up Period | Health-Related Outcomes | SD | RM | Cit. |
---|---|---|---|---|---|---|---|
Healthy adults | Dietary intake of any edible mushrooms at least two-to-three times a week | Less than one serving of mushrooms per week | 5–26 years | ↓ Breast cancer incidence RR = 0.65 [95% CI: 0.52; 0.81] ↓ Non-breast cancer incidence RR = 0.80 [95% CI: 0.66; 0.97] | SR + MA (17 studies) | PRISMA | [6] |
Adults interviewed about their nutritional habits | Dietary intake of any edible mushrooms | No mushroom consumption | 6–27 years | ↓ All-cause mortality risk RR = 0.94 [95% CI: 0.91; 0.98] | SR + MA (4 studies) | PRISMA | [7] |
Healthy adults or patients with cardiometabolic risk factors | Oyster mushroom (Pleurotus ostreatus) 10–200 g/day (lyophilized or fresh) | No mushroom consumption | 7 days–1 year | ↓ Fasting plasma glucose (6–22%) ↓ Total cholesterol (8–24%) ↓ Triglycerides (20–36%) ↔ HDL cholesterol ↔ Blood pressure ↔ Body weight | SR (7 studies) | PRISMA | [8] |
Adults interviewed about their nutritional habits | Dietary intake of any edible mushrooms | No mushroom consumption | Mostly 3–24 weeks | ↓ Total cholesterol ↓ Triglycerides ? Blood pressure ↔ Fasting plasma glucose | SR (7 studies) | - | [9] |
Healthy adults | Dietary intake of any edible mushrooms | Vitamin D supplementation | ~1 month | ↑ Vitamin D levels (as much as with vitamin D supplementation) | NR | - | [10] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Antonelli, M.; Donelli, D. Dietary Consumption of Edible Mushrooms for Disease Prevention: A Literature Overview. Biol. Life Sci. Forum 2023, 26, 19. https://doi.org/10.3390/Foods2023-15049
Antonelli M, Donelli D. Dietary Consumption of Edible Mushrooms for Disease Prevention: A Literature Overview. Biology and Life Sciences Forum. 2023; 26(1):19. https://doi.org/10.3390/Foods2023-15049
Chicago/Turabian StyleAntonelli, Michele, and Davide Donelli. 2023. "Dietary Consumption of Edible Mushrooms for Disease Prevention: A Literature Overview" Biology and Life Sciences Forum 26, no. 1: 19. https://doi.org/10.3390/Foods2023-15049